Merck and Moderna Report First Positive Phase 3 for a Personalized mRNA Cancer Vaccine in High-Risk Melanoma
Merck and Moderna on August 19 announced the first positive Phase 3 readout for a personalized mRNA cancer vaccine — mRNA-4157 combined with Keytruda — in high-risk resected melanoma. The combination reduced the risk of recurrence or death by 44 percent versus Keytruda alone, with a hazard ratio of 0.56 over a median 34-month follow-up.